Alexandra Calmy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2939700/publications.pdf

Version: 2024-02-01

110	3,722	136885	149623
papers	citations	32 h-index	56 g-index

115	115	115	5562
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV,the, 2015, 2, e438-e444.	2.1	227
2	HIV Viral Load Monitoring in Resourceâ€Limited Regions: Optional or Necessary?. Clinical Infectious Diseases, 2007, 44, 128-134.	2.9	226
3	Dolutegravir-Based or Low-Dose Efavirenzâ€"Based Regimen for the Treatment of HIV-1. New England Journal of Medicine, 2019, 381, 816-826.	13.9	196
4	Life expectancy in HIV-positive persons in Switzerland. Aids, 2017, 31, 427-436.	1.0	193
5	Benefits and risks of rapid initiation of antiretroviral therapy. Aids, 2018, 32, 17-23.	1.0	191
6	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	15.2	133
7	HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. Aids, 2009, 23, 929-939.	1.0	130
8	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVIDâ€19: initial assessment. Journal of the International AIDS Society, 2020, 23, e25489.	1.2	116
9	The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infectious Diseases, The, 2015, 15, 241-247.	4.6	115
10	HIV and antiretroviral therapy-related fat alterations. Nature Reviews Disease Primers, 2020, 6, 48.	18.1	104
11	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	1.8	101
12	Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV,the, 2020, 7, e677-e687.	2.1	86
13	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2019, 6, e116-e127.	2.1	84
14	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	0.9	69
15	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. Annals of Internal Medicine, 2021, 174, 758-767.	2.0	66
16	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2016, 62, 115-122.	2.9	60
17	Expert consensus statement on the science of <scp>HIV</scp> in the context of criminal law. Journal of the International AIDS Society, 2018, 21, e25161.	1.2	59
18	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine, 2020, 28, 100573.	3.2	54

#	Article	IF	Citations
19	Disentangling Human Tolerance and Resistance Against HIV. PLoS Biology, 2014, 12, e1001951.	2.6	53
20	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases, 2016, 62, 1310-1317.	2.9	52
21	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. Aids, 2012, 26, 2079-2086.	1.0	47
22	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2016, 214, 399-402.	1.9	47
23	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. European Heart Journal, 2018, 39, 2147-2154.	1.0	47
24	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	13.7	47
25	A new era of antiretroviral drug toxicity. Antiviral Therapy, 2009, 14, 165-179.	0.6	47
26	Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infectious Diseases, The, 2013, 13, 303-312.	4.6	46
27	Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa â€" A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e82724.	1.1	43
28	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV,the, 2020, 7, e193-e200.	2.1	41
29	Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). PLoS ONE, 2015, 10, e0140943.	1.1	40
30	Virological Outcomes of Second-line Protease Inhibitorâ€"Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clinical Infectious Diseases, 2017, 64, 1006-1016.	2.9	37
31	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	3.5	37
32	Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2015, 2, ofv077-ofv077.	0.4	35
33	Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. Clinical Infectious Diseases, 2015, 60, S170-S176.	2.9	35
34	Universal test and treat is not associated with subâ€optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. Journal of the International AIDS Society, 2018, 21, e25112.	1.2	34
35	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. F1000Research, 2018, 7, 1359.	0.8	31
36	HIV treatment for prevention. Journal of the International AIDS Society, 2011, 14, 28-28.	1.2	30

#	Article	IF	Citations
37	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infectious Diseases, 2015, 15, 382.	1.3	29
38	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	4.2	29
39	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.4	28
40	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	1.9	27
41	Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring and Self-Report in Cameroon. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 216-219.	0.9	25
42	Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship*. Journal of Antimicrobial Chemotherapy, 2015, 70, 225-232.	1.3	24
43	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)â€“Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clinical Infectious Diseases, 2018, 66, 1099-1108.	2.9	24
44	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€2017. Journal of the International AIDS Society, 2019, 22, e25339.	1.2	24
45	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. F1000Research, 2018, 7, 1359.	0.8	24
46	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	0.9	24
47	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 2017, 64, 1275-1278.	2.9	23
48	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitorâ€“Based Antiretroviral Treatment. Clinical Infectious Diseases, 2021, 73, e2134-e2141.	2.9	23
49	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLâ€™HIV trial. PLoS Medicine, 2020, 17, e1003421.	3.9	23
50	Incidence of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome and Impact on Patient Outcome. PLoS ONE, 2013, 8, e84585.	1.1	22
51	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. Journal of Infectious Diseases, 2020, 222, 637-645.	1.9	22
52	Prophylaxis for COVID-19: a systematic review. Clinical Microbiology and Infection, 2021, 27, 532-537.	2.8	21
53	A new era of antiretroviral drug toxicity. Antiviral Therapy, 2009, 14, 165-79.	0.6	21
54	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. Journal of Infectious Diseases, 2015, 212, 578-584.	1.9	20

#	Article	IF	Citations
55	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. Open Forum Infectious Diseases, 2019, 6, ofz277.	0.4	20
56	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterology, 2015, 15, 79.	0.8	18
57	Dexamethasone and remdesivir: finding method in the COVID-19 madness. Lancet Microbe, The, 2020, 1, e309-e310.	3.4	18
58	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	2.2	17
59	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€"Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
60	Weight gain stopping/switch rules for antiretroviral clinical trials. Aids, 2021, 35, S183-S188.	1.0	15
61	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. Journal of Infection, 2018, 76, 186-195.	1.7	12
62	Cardiovascular risk assessment in people living with HIV compared to the general population. European Journal of Preventive Cardiology, 2022, 29, 689-699.	0.8	12
63	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. Journal of Clinical Medicine, 2021, 10, 295.	1.0	11
64	Higher Memory Responses in HIV-Infected and Kidney Transplanted Patients than in Healthy Subjects following Priming with the Pandemic Vaccine. PLoS ONE, 2012, 7, e40428.	1.1	11
65	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clinical Infectious Diseases, 2020, 70, 297-303.	2.9	10
66	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, 2018, 5, ofy078.	0.4	8
67	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	1.3	7
68	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	1.2	7
69	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
70	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 492-499.	1.3	7
71	Approaches to accelerating the study of new antiretrovirals in pregnancy. Journal of the International AIDS Society, 2022, 25, .	1.2	7
72	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infectious Diseases, 2019, 19, 834.	1.3	6

#	Article	IF	Citations
73	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	1.9	6
74	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. Aids, 2021, Publish Ahead of Print, 2469-2480.	1.0	6
75	Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries. JMIR MHealth and UHealth, 2019, 7, e13741.	1.8	6
76	A buyersâ€™ club to improve access to hepatitis C treatment for vulnerable populations. Swiss Medical Weekly, 2018, 148, w14649.	0.8	6
77	Dexamethasone exposure in normalâ€weight and obese hospitalized <scp>COVID</scp>â€19 patients: An observational exploratory trial. Clinical and Translational Science, 2022, 15, 1796-1804.	1.5	6
78	Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action. Journal of the International AIDS Society, 2022, 25, .	1.2	6
79	Switch to etravirine for <scp>HIV</scp>â€positive patients receiving statin treatment: a prospective study. European Journal of Clinical Investigation, 2015, 45, 720-730.	1.7	5
80	Mesenterial involvement of Mycobacterium genavense infection: hard to find, hard to treat. BMJ Case Reports, 2015, 2015, bcr2014208241-bcr2014208241.	0.2	5
81	Will NNRTIs be driving forward again?. Lancet HIV,the, 2018, 5, e200-e201.	2.1	5
82	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nature Communications, 2020, 11, 5542.	5.8	5
83	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 2020, 224, 1198-1208.	1.9	5
84	The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. International Journal of STD and AIDS, 2021, 32, 729-739.	0.5	5
85	Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs. Frontiers in Medicine, 2021, 8, 685124.	1.2	5
86	Caring for people living with HIV during the global coronavirus disease 2019 pandemic. Aids, 2021, 35, 355-358.	1.0	5
87	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, 2021, 42, 101188.	3.2	5
88	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. Open Forum Infectious Diseases, 2020, 7, ofaa438.	0.4	4
89	Cyber harassment of female scientists will not be the new norm. Lancet Infectious Diseases, The, 2021, 21, 457-458.	4.6	4
90	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 1592-1600.	1.9	4

#	Article	IF	Citations
91	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. Journal of Antimicrobial Chemotherapy, 2019, 74, 2468-2470.	1.3	3
92	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. PLoS ONE, 2021, 16, e0246579.	1.1	3
93	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. Clinical Infectious Diseases, 2022, 74, 1468-1475.	2.9	3
94	Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals. Current Vascular Pharmacology, 2015, 13, 167-172.	0.8	3
95	Impact of Latent Tuberculosis on Diabetes. Journal of Infectious Diseases, 2022, 225, 2229-2234.	1.9	3
96	HIV and Ebola virus. Aids, 2015, 29, 1593-1596.	1.0	2
97	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	2.9	2
98	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. Nature Communications, 2021, 12, 1219.	5.8	2
99	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. Antiviral Therapy, 2020, 25, 43-54.	0.6	2
100	Is monotherapy maintenance the way forward?. Lancet HIV,the, 2015, 2, e402-e403.	2.1	1
101	Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. Annals of Hematology, 2019, 98, 1317-1318.	0.8	1
102	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravirâ€based regimens in SIMPL'HIV clinical trial. British Journal of Clinical Pharmacology, 2021, 87, 4455-4460.	1.1	0
103	Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfected patients: a substudy of the CARINEMO-ANRS12146 trial. F1000Research, 0, 8, 169.	0.8	0
104	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	0
105	Title is missing!. , 2020, 17, e1003421.		0
106	Title is missing!. , 2020, 17, e1003421.		0
107	Title is missing!. , 2020, 17, e1003421.		0
108	Title is missing!. , 2020, 17, e1003421.		0

#	Article	IF	Citations
109	Title is missing!. , 2020, 17, e1003421.		0
110	Title is missing!. , 2020, 17, e1003421.		0